Pharma BD Deal Intelligence
The $2.1B bet on an unapproved radioligand became Pluvicto, a $2B/yr (and rising toward $5B by 2030) blockbuster and the anchor of Novartis's radioligand therapy platform.
Full analysis, sources & comparables →Novartis acquired Endocyte for $2.1B for 177Lu-PSMA-617 radiopharmaceutical candidate.
VISION Phase 3 trial showed 177Lu-PSMA-617 plus standard care extended OS by 4.0 months (HR 0.62) versus standard care alone in mCRPC — landmark data…
Acquirer SEC 6-K (Tier 2); Pluvicto FY2025 net sales USD 605M, +70% cc — validates the radioligand-platform acquisition thesis.
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Novartis announced October 2018 acquisition of Indiana-based Endocyte for $24/share cash, total equity value $2.1B. Adds Phase 3 177Lu-PSMA-617 (later Pluvicto), a first-in-class PSMA-targeted radioligand therapy for mCRPC, plus preclinical 225Ac-PSMA-617. Builds on Novartis's January 2018 AAA acquisition (Lutathera) to consolidate radiopharmaceuticals leadership. Closed December 21, 2018; Pluvicto won initial FDA approval in post-taxane mCRPC in March 2022. The acquisition thesis has since strengthened: on March 28, 2025 the FDA approved Pluvicto for earlier, pre-taxane use in PSMA-positive mCRPC (PSMAfore trial: 59% reduction in risk of radiographic progression/death; rPFS 11.6 vs 5.6 months), roughly tripling the eligible patient population. On June 2, 2025 the Phase 3 PSMAddition trial met its primary rPFS endpoint in metastatic hormone-sensitive prostate cancer (HR 0.72) with a regulatory submission planned. Pluvicto generated USD 605M in FY2025 net sales (+70% cc), confirming the radioligand-platform bet behind the Endocyte deal.
The $2.1B bet on an unapproved radioligand became Pluvicto, a $2B/yr (and rising toward $5B by 2030) blockbuster and the anchor of Novartis's radioligand therapy platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Endocyte, Inc. (this deal) | 2018 | $2.1B | 96 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2018 deals · Novartis AG deals · Oncology deals